European Journal of Cancer
Volume 41, Issue 14 , Pages 2071-2078, September 2005

Cancer staging and survival in colon cancer is dependent on the quality of the pathologists’ specimen examination

  • P. Jestin

      Affiliations

    • The Department of Surgical Sciences, Akademiska sjukhuset, Colorectal Unit, Uppsala University, SE 751 85, Uppsala, Sweden
    • Corresponding Author InformationCorresponding author. Fax: +46 18 6114632.
  • ,
  • L. Påhlman

      Affiliations

    • The Department of Surgical Sciences, Akademiska sjukhuset, Colorectal Unit, Uppsala University, SE 751 85, Uppsala, Sweden
  • ,
  • B. Glimelius

      Affiliations

    • Department of Oncology, Radiology and Clinical Immunology, Akademiska sjukhuset, Uppsala University, Uppsala, Sweden
  • ,
  • U. Gunnarsson

      Affiliations

    • The Department of Surgical Sciences, Akademiska sjukhuset, Colorectal Unit, Uppsala University, SE 751 85, Uppsala, Sweden

Received 15 December 2004; received in revised form 26 May 2005; accepted 16 June 2005.

Abstract 

Correct staging of colon cancer is decisive regarding further oncological treatment, surveillance and prediction of long-term survival. This study investigated the variability in accuracy of pathology reports with focus on differences between pathology departments and their compliance to regional guidelines. Data from the colon cancer register (1997–2002) of the Uppsala/Örebro, Sweden, health care region were analysed and the seven pathology departments in this region were compared. Included were 3735 patients who had undergone resection of a colon cancer. Cumulative 5-year survival was the main end-point.

For 64% (n=2390) of the cases, the number of lymph nodes examined was given (median 8). Survival in stage II was lower when fewer than 12 nodes were examined or when the number of nodes sampled was not given (P=0.001, log-rank test). In stage III, those with at the most 3 nodes positive (N1) had a better survival than those with 4 or more nodes positive (N2) (P<0.001, log-rank test). An index of metastases (IM), derived from the number of nodes with metastases divided by the number of nodes examined, was calculated for stage III tumours. Examination of 12 nodes is necessary to assure stage III cases with the median IM (0.32), whereas 20 nodes are necessary to assure 90% of cases with the lower quartile of IM (0.16). Irrespective of the number of nodes investigated, overall survival was better among patients with IM<0.33 vs. IM0.33 (P<0.001, log-rank test). The prognostic information of the IM was higher than that of the N-stage. Quality of a pathology department, measured by the median number of lymph nodes investigated and by the proportion of reports where the number is given, was determined to indicate correct staging and management of the patient. An index of metastases (IM) is a possible basis for guidance in the choice of adjuvant treatments that appears superior to that of N-stage.

Keywords: Colon cancer, Epidemiology, Quality control, Lymph nodes, Tumour staging, Survival

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S0959-8049(05)00546-0

doi:10.1016/j.ejca.2005.06.012

European Journal of Cancer
Volume 41, Issue 14 , Pages 2071-2078, September 2005